Strides Shasun gets USFDA nod for kidney stone tablets
New Delhi: Strides Shasun on Tuesday said it has received approval from the US health regulator for potassium citrate extended release tablets used to prevent certain types of kidney stones.
In a BSE filing, Strides Shasun said it has received approval from the United States Food and Drug Administration (US FDA) for potassium citrate extended release tablets USP 5 mEq, 10 mEq and 15 mEq.
Strides Shasun said it will be the second generic player to commercialize the product and will launch it immediately.
Citing IMS sales data, the company said the US market for the approved product is approximately USD 110 million.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd